The short-term clinical investigation of ticagrelor in reducing cardiovascular MACEs for elective PCI patients with stable coronary heart disease.
Phase of Trial: Phase IV
Latest Information Update: 23 Aug 2016
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Coronary artery disease
- Focus Pharmacodynamics
- 21 Aug 2016 Status changed from recruiting to completed.
- 19 Mar 2014 New trial record